Fig 2: Apatinib inhibits the invasive ability of the HGC-27 cell line. A Transwell assay was used to determine the invasive abilities of HGC-27 cells in the (A) control group, (B) IL-17 group, (C) IL-17-apatinib group and (D) apatinib group. Scale bar, 100-µm. (E) Semi-quantification of the invasive cells number calculated from parts (A-D). Data are presented as the mean ± SD (n=3). A one-way ANOVA followed by a Tukey's post hoc test was used for the statistical analysis. **P<0.01.

Fig 3: Effect of apatinib and IL-17 on cell apoptosis. Flow cytometric analysis of apoptosis was performed in HGC-27 cells in the (A) control group, (B) IL-17 group, (C) IL-17-apatinib group and (D) apatinib group. (E) Quantification of the apoptotic rate in the four groups from parts (A-D). Data are presented as the mean ± SD (n=3). A one-way ANOVA followed by a Tukey's post hoc test was used for the statistical analysis. **P<0.01. 7-AAD, 7-aminoactinomycin D; APC, allophycocyanin.

Fig 4: MTT assay analysis of the effect of IL-17 and apatinib on the proliferation of the HGC-27 cell line. Data are presented as the mean ± SD (n=3). A one-way ANOVA followed by a Tukey's post hoc test was used for the statistical analysis. **P<0.01.

Fig 5: Expression levels of IL-17 in gastric carcinoma and para-carcinoma tissues. (A) Reverse transcription-quantitative PCR and (B) western blotting were used to determine the mRNA and protein expression levels, respectively, of IL-17 in the gastric carcinoma and para-carcinoma tissues. Data are presented as the mean ± SD (n=3). A paired Student's t-test was used for the statistical analysis. **P<0.01.